PharmaNet hires vp for clinical operations

Catherine Derasp will oversee Phase I clinics

Catherine Derasp has joined PharmaNet Development Group, a US provider of clinical development services to the pharmaceutical and biotechnology industry, as vice president, clinical operations of the company's Phase I clinics.

Derasp will oversee the management of the company's 350-bed Phase I clinical operations that are located in Montreal and Quebec City, Canada. In addition to first-in-man and proof-of-concept phase I clinical services, she will be responsible for a variety of studies in special populations, cardiac safety testing, and drug-drug interaction studies.

You may also like

Regulatory

Pfizer and BioNTech’s COMIRNATY COVID-19 vaccine wins FDA approval for seniors and high-risk individuals

The COVID-19 vaccines by Pfizer and BioNTech are based on BioNTech’s proprietary mRNA technology and were developed by both companies
Regulatory

Roca secures EMA recognition of radiation maculopathy as a distinct indication and Orphan Drug Designation

Roca Therapeutics (Roca) announces the granting of Orphan Drug Designation (ODD) by the European Medicines Agency (EMA) for its lead clinical candidate, RCT002, to treat radiation maculopathy
Manufacturing

Suncombe launches compact pH neutralisation systems for labs and small facilities

Expanded SUNpH range delivers compliance and performance in space-limited settings
Pharmaceutical

Enanta Pharma files patent infringement suit against Pfizer in the Unified Patent Court of the EU

The company is seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the 265 Patent) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets)
Regulatory

Filter manufacturer maintains official seal of approval for health and safety

Inspectors from health and safety standards body BSI have praised a process filter maker’s “thorough and well-organised approach” to workplace safety management
Manufacturing

One family’s journey from diagnosis to gene replacement therapy

How the Krueger family, supported by clinicians, researchers, and manufacturers, accelerated a novel treatment for ultra-rare NEDAMSS in just 14 months
Regulatory

WuXi Biologics Ireland receives EMA approval to manufacture an innovative biologic

This approval adds to WuXi Biologics’ multiple facilities, which have received EMA and FDA approvals for commercial manufacturing of the same product since 2023
Subscribe now